Impax Laboratories — Investor Presentation (February 2007)
29 slides from Impax Laboratories's investor presentation, Feb 7, 2007
Slide 1: IMPAX Laboratories, Inc. February 2007
IMPAX Laboratories, (fe. & es February 2007 v1
Slide 2: Safe Harbor statement
IMPAX Laboratories, Inc. (IPXL.PK) "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expecta
Slide 3: Company Overview
Company Overview Technology based specialty pharmaceutical company Applying oral drug delivery technology and formulation expertise to the development of generic and branded pharmaceutical products Experienced senior management team Strong product portfolio Brand strategy offers potential long-term
Slide 4: Product Portfolio
Product Portfolio Approximately 110 generic products approved, pending or under development - targeting over $30 billion in US product sales 36 Approved applications 22 Applications pending at FDA 5 ANDAs with Tentative Approval Approximately 52 more under development Additional products and/or stre
Slide 5: R&D Highlights 2006
R&D Highlights 2006 - Received 6 approvals from FDA Final Approvals for generic versions of: Salagen Colestid Granules Colestid Tablets Urecholine Ditropan XL 15mg Wellbutrin XL 300mg
Slide 6: Commercial Highlights 2006
Commercial Highlights 2006 - Launched 6 new products Includes generic versions of: Salagen 5, 7.5mg Colestid Granules Lofibra 67, 134, 200mg ProAmatine 10mg Ditropan XL 15mg Wellbutrin XL 300mg
Slide 7: Drug Delivery Capabilities
Drug Delivery Capabilities Multiple delivery vehicles Applying new and existing drug delivery technologies to create new product opportunities (19 approved ANDAs utilize our drug delivery technologies) Developing and patenting new concepts and oral controlled release technologies Approximately 120 e
Slide 8: Development Strategy
Development Strategy Target limited competition environment Generic Controlled Release - large, rapidly growing market Specialty - technically challenging projects, barriers to entry, or other selected market opportunities Brand Targeting drugs used in treating CNS disorders Focusing on improved ver
Slide 9: Development Strategy: Outsourced Development
Development Strategy Outsourced Development Selected Generic Projects 21 development projects outsourced Utilizing 6 off-shore companies Out of the 21 projects, 6 have been submitted Provides Lower cost of development Increased development capacity
Slide 10: Generic Projects
February 2007 v1 Generic Projects IMPAX Laboratories, . tne,
Slide 11: Generic Projects Current Status
Generic Projects Current Status *US Market size, millions of US$ Group Specialty Specialty Controlled Release Controlled Release Total Total Category Qty Market* Qty Market* Qty Market* Pending at FDA 11 $779 11 $6,860 22 $7,639 Under Development 15 $3,037 37 $14,947 52 $17,984 Total 26 $3,816 48 $2
Slide 12: Paragraph IV Filing Summary (24 total)
Paragraph IV Filing Summary (24 total) Generic Projects *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 1:Paragraph IV cert. & notice filed 4Q02. Products in Teal are marketed. White background means TA/FA rec'd. IMPAX Project G
Slide 13: Paragraph IV Filing Summary
Paragraph IV Filing Summary Generic Projects *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 2--Paragraph IV certification and notice filed 3Q05. Note 3--First to file on 15 mg strength. IMPAX Project Generic of* Est. Filing Ord
Slide 14: Paragraph IV Litigation Status Summary
Paragraph IV Litigation Status Summary (24 total filed) Generic Projects Litigation Resolved or Not Sued (16 projects) Litigation Resolved or Not Sued (16 projects) Bupropion 100,150mg ER (W) Methylphenidate 18,27,36&54mg ER Bupropion 150mg ER (Z) Carbidopa/Levodopa ER Fenofibrate 67,134,200mg Caps
Slide 15: Paragraph IV Litigation Status Summary
Paragraph IV Litigation Status Summary (24 total filed) Generic Projects Project Litigation Status Omeprazole 10, 20 & 40mg DR Trial completed June 2006; awaiting decision. Fexofenadine & PSE ER No trial date scheduled. Oxycodone 80mg ER Litigation starting. Purdue v. Endo case remanded by CAFC and
Slide 16: Strategic Alliances: Teva
Commercial Strategy Strategic Alliances for Generic Projects Teva (Rx Partners) Signed June 2001 First product shipped 1Q 2004 12 Rx products 11 filed to date 11 disclosed Omeprazole 10,20, 40mg DR Bupropion 100,150 mg ER (W) Bupropion 150 mg ER (Z) Bupropion 150, 300 mg ER (XL) Loratadine OD Lorata
Slide 17: Strategic Alliances: Dava
Commercial Strategy Strategic Alliances for Generic Projects Dava (Rx Partners) Signed November 2005 Ten year exclusive agreement Payments of $60 million to be received over five years Profit split First product shipped 4Q 2005 Products Licensed: Oxycodone 10, 20 40 mg ER Oxycodone 80 mg ER
Slide 18: Shire Settlement
Commercial Strategy Generic Projects Shire (Settlement) Settlement agreements signed January 2006 Provide for dismissal of all lawsuits and claims related to Impax Paragraph IV filings for generic versions of Shire's Adderall(r) XR Market entry date no later than January 1, 2010 Earlier launch if an
Slide 19: Brand Projects
February 2007 v1 Brand Projects IMPAX Laboratories, . tne,
Slide 20: Brand Projects: Improved Versions of Existing Entities
Brand Projects Targeting improved versions of existing chemical entities Reduced risk and expense associated with development as compared to NCE development. Reduced time of development as compared to NCE development Utilize development and drug delivery expertise Improve patient compliance and outc
Slide 21: Brand Projects: CNS Focus
Brand Projects Focus on Central Nervous System (CNS) drugs Rapidly growing therapeutic area Focus on CNS disease states, including movement disorders such as Parkinson's disease. These movement disorders are frequently treated by the approximately 8,300 practicing neurologists, of which about 3,500
Slide 22: Brand Projects: Unmet Needs in Parkinson's Disease
Brand Projects Despite being the standard for treating Parkinson's Disease, existing levodopa therapy does not meet certain needs: Delayed or unpredictable "on" Motor fluctuation and dyskinesias Pill burden True delivery of continuous dopaminergic stimulation
Slide 23: Brand Projects: VADOVA
Brand Projects VADOVATM (carbidopa-levodopa) is formulated with the goal of meeting one of these unmet needs by allowing a reduction in pill burden.
Slide 24: VADOVA NDA Status
Brand Projects The effective date of acceptance of the VADOVA NDA by FDA was May 3, 2005. "Non-approvable" letter received from FDA March 3, 2006. An Amendment was filed on January 18, 2007 addressing the concerns raised in the Agency's non-approvable letter of March 2006. US and foreign patent appl
Slide 25: Strategic Alliances: Carbatrol (Shire)
Commercial Strategy Strategic Alliances for Branded Projects Carbatrol (r) (Shire) Signed January 2006 Three year exclusive agreement Payments of $40 million to be received over three years to provide promotional services Target audience - Neurologists Impax Pharmaceuticals Sales Force formed and Ca
Slide 26: Significant Milestones
Significant Milestones Milestone 2000/2001 2002 2003 2004 2005 2006 2007 (YTD) Applications Filed 16 8 8 6 10 6 1 PPG IV filings 9 5 4 1 3* 1 1 IND filings 0 0 2 1 0 0 0 NDA filings 0 0 0 0 1 0 0 Approvals (Total) 3 8 9 11 6 6 0 Tentative approval 0 5 2 2 1 1 0 Strategic Alliances Teva, Novartis Wye
Slide 27: Financials
Financials DecOS5 Mar06 Jun06% Sep06 Dec-06 (in thousands and unaudited) Cash and Investments 56,077 41,438 «30,695 27,353 29,092 Senior Debt 5396 5,369 5342 5316 5,430 Convertible & Subordinated Debt 75,000 75,000 75,000 75,000 75,000 Subordinated Settlement Obligation 11,000 11,000 11,000 Total Se
Slide 28: Highlights
Highlights Experienced management with strong industry knowledge and technical expertise Broad base of drug delivery technology, formulation and development expertise Strong product portfolio Branded product strategy offers potential additional long-term growth opportunities
Slide 29: Thank you for your interest in IMPAX Laboratories, Inc.
Thank you for your interest in IMPAX Laboratories, Inc.
Impax Laboratories — Investor Presentation (February 2007) on 6ix